Evidence map›Paper›PMID 40967796›Full record

ArticleInternal medicine (Tokyo, Japan)2026

Severe Immune Checkpoint Inhibitor-associated Gastritis Treated with Steroids and Infliximab.

Koki Tanaka, Toshiyuki Morisawa, Norio Katayama, Kazuki Inoue, Daiki Fumihara, Megumi Takagi, Tomoya Sako, Kenji Momose, Mari Noda, Keisuke Furumatsu

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Koki TanakaDepartment of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, Japan.
Toshiyuki MorisawaDepartment of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, Japan.
Norio KatayamaDepartment of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, Japan.
Kazuki InoueDepartment of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, Japan.
Daiki FumiharaDepartment of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, Japan.
Megumi TakagiDepartment of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, Japan.
Tomoya SakoDepartment of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, Japan.
Kenji MomoseDepartment of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, Japan.
Mari NodaDepartment of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, Japan.
Keisuke FurumatsuDepartment of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This case report describes a 77-year-old man with severe immune-related gastritis after receiving pembrolizumab for lung cancer. Despite initial steroid therapy, he showed no improvement and was diagnosed with steroid refractory immune-related gastritis. Infliximab was added to steroid therapy, resulting in significant clinical and endoscopic improvement. This highlights the importance of early diagnosis of immune-related gastritis by endoscopic and histological findings. Prompt evaluation of steroid efficacy and the early use of infliximab in steroid refractory cases are emphasized for effective management of immune-related gastritis as the indications for immune checkpoint inhibitors have expanded.

Indexed as

Antibodies, Monoclonal, HumanizedGastritisImmune Checkpoint InhibitorsInfliximabSteroidsAgedDrug Therapy, CombinationHumansLung NeoplasmsMaleTreatment OutcomeAntibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsInfliximabpembrolizumabSteroidsgastritisimmune checkpoint inhibitorimmune-related adverse eventinfliximabpembrolizumabsteroid-refractory

Identifiers

PMID40967796
PMCPMC13175655

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.